Biologically Active Substance
AbbVie’s Rinvoq cleared for giant cell arteritis in US
Giant Cell Arteritis, Rinvoq, upadacitinib, Approved, Janus kinase, Inhibitor, United States Food and Drug Administration, Steroids
Merck & Co. breaks ground on $1B future US home of Keytruda
United States, Keytruda, Home environment, Merck, Wilmington, Biological Factors
FDA decision on Stealth’s Barth syndrome drug delayed, again
United States Food and Drug Administration, 3-Methylglutaconic aciduria type 2, Decision, Elamipretide
Pfizer’s Sasanlimab Shows 32% Reduction in Bladder Cancer Risk But Misses Secondary Endpoints in Phase 3 CREST Trial
Sasanlimab (PD-1 inhibitor), Bladder cancer risk reduction, Phase 3 CREST trial, BCG combination therapy, Non-muscle invasive bladder cancer (NMIBC), Event-free survival (EFS), Overall survival (OS) endpoint missed, Subcutaneous administration
Roche’s WRN Inhibitor Shows Promising Early Results in MSI-H Tumors at AACR25
Roche, WRN inhibitor, MSI-H tumors, AACR25, cancer research, oncology
Akeso’s PD-1 inhibitor notches inaugural FDA nod for nasopharyngeal cancer
United States Food and Drug Administration, Approved, Akeso, Nasopharyngeal carcinoma, PDCD1 gene, Inhibitor, Akeso ‘s, Anniko
Compounding pharmacies dealt a blow in fight over end of semaglutide shortage
United States Food and Drug Administration, semaglutide, Compound, enforcement, Pharmacy facility, shortage, Wegovy
Lotte Bio launches ADC services; Ypsomed to focus on self-injection business
Antibody-Drug Conjugates, Lotte, Ypsomed, Services, Biological Factors, Manufacture, self-injection business
Novavax’s COVID-19 jab looks to be on track for approval
Vaccines, COVID19 (disease), United States Food and Drug Administration, Approved, Novavax, Novavax ‘s, Novavax
Regeneron turns to CDMO Fujifilm to boost US manufacturing capacity
Regeneron, Manufacture, Fujifilm, CDMO, Biological Factors, Capacity, United States, Boost